Chiesi

Trimbow®

beclometasone/formoterol/
glycopyrronium 87/5/9 & 88/5/9
Extrafine formulation

Have you triple checked your patients with COPD?

Trimbow pMDI 87/5/9 and NEXThaler 88/5/9 are indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β_2-agonist or a combination of a long-acting β_2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1 of the SPC).[1,2] Fostair pMDI and NEXThaler 100/6 are indicated for the symptomatic treatment of adult patients with severe COPD (FEV_1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.[3,4]

Prescribing Information and Adverse Event reporting can be found at the end of this document.

UK-TRI-2500084 June 2025

Optimise care for your adult patients with moderate to severe COPD

According to GOLD recommendations, it is important to regularly monitor patients as this allows for a more tailored approach in effectively managing COPD.[5]

THE TRIPLE CHECK SYSTEM

Use the triple check system to identify which of your patients with moderate to severe COPD – currently treated with **ICS/LABA** or **ICS/LABA + LAMA via multiple inhalers** – could benefit from a single inhaler triple therapy.

THINK	SYMPTOMS	ADHERENCE	DEVICE
ASK	Are the patient's symptoms adequately controlled?	Could adherence be impacting treatment outcomes?	Is the patient using the most suitable device (pMDI or DPI) for their needs?
ACTION	If **NO**, consider escalating their therapy, while keeping the number of inhalers to a minimum to help improve lung function and reduce further exacerbations[5,6]	If **YES**, consider moving to a single device for patient convenience[5]	If **NO**, assess their inhaler technique and make a joint decision about the most suitable device as recommended by guidelines[5,7]

Choose Trimbow, in either a pMDI or NEXThaler® (DPI), for your appropriate adult patients with moderate to severe COPD

Chiesi

Trimbow®

beclometasone/formoterol/
glycopyrronium 87/5/9 & 88/5/9
Extrafine formulation

Think triple (ICS/LABA/LAMA), Think Trimbow



Extrafine formulation like Fostair® (beclometasone/formoterol)[1–4]

Choice of device to help meet your patients' needs[1,2]

The Click of Confidence with NEXThaler for you and your patients who need a DPI[2,8]

- Confidence for your patients through confirmed dose delivery[2,8]

A familiar pMDI device for your patients who need it[1,9,10]

Trimbow pMDI 87/5/9 demonstrated:

- Similar rates of moderate to severe exacerbations vs. multiple inhalers (Fostair pMDI 100/6 + Spiriva® HandiHaler® [RR 1.01]) – secondary endpoint[1,11]
- Reduction in moderate to severe exacerbations vs. ICS/LABA (Fostair pMDI 100/6) – secondary endpoint[1,12]*

Click here or scan to explore a range of COPD patient support materials on ChiesiAir.co.uk

COPD: chronic obstructive pulmonary disease; **DPI:** dry powder inhaler; **FEV_1:** forced expiratory volume in one second; **GOLD:** Global Initiative for Chronic Obstructive Lung Disease; **ICS:** inhaled corticosteroid; **LABA:** long-acting β_2-agonist; **LAMA:** long-acting muscarinic antagonist; **N:** number of patients; **pMDI:** pressurised metered dose inhaler; **RR:** (adjusted) rate ratio; **SPC:** summary of product characteristics; **TDI:** Transition Dyspnea Index.

*Co-primary endpoints of TRILOGY: Superiority of Trimbow pMDI 87/5/9 vs. Fostair pMDI 100/6 was met in change from baseline in pre-dose morning FEV_1 ($p<0.001$), change from baseline in 2-h post-dose FEV_1 ($p<0.001$), but unmet for TDI focal score ($p=0.160$), all assessed at week 26 (N=1,368).[12] As one of the co-primary endpoints in the TRILOGY study did not achieve statistical significance, p-values shown for the TRILOGY study are descriptive.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.

Certified B Corporation

References

1. Trimbow pMDI 87/5/9 Summary of Product Characteristics. Chiesi Limited.
2. Trimbow NEXThaler 88/5/9. Summary of Product Characteristics. Chiesi Limited.
3. Fostair pMDI 100/6 Summary of Product Characteristics. Chiesi Limited.
4. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
5. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2025. Available at: https://goldcopd.org/2025-gold-report/.
6. NICE. Guideline NG115. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2019. Available at: https://www.nice.org.uk/guidance/ng115/chapter/Recommendations.
7. Kaplan A, Price D. *Can Respir J*. 2018; 9473051.
8. Voshaar T, *et al*. *J Aerosol Med Pulm Drug Deliv*. 2014; 27(5): 363–370.
9. LRX. R3F Group Data. Dec 2023.
10. IQVIA XBPI MAT. Dec 2023.
11. Vestbo J, *et al*. *Lancet*. 2017; 389(10082): 1919–1929.
12. Singh D, *et al*. *Lancet*. 2016; 388(10048): 963–973.

Click here or scan to view Trimbow Prescribing Information

Click here or scan to view Fostair Prescribing Information